Similar articles

• Adverse drug reactions: a pharmacist-based monitoring system.

  Gardner P, Watson LJ. Gardner P, et al. Clin Pharmacol Ther. 1970 Nov-Dec;11(6):802-7. doi: 10.1002/cpt1970116802. Clin Pharmacol Ther. 1970. PMID: 5481567 No abstract available.
• Statistical problems in monitoring adverse drug reactions.

  Moussa MA. Moussa MA. Methods Inf Med. 1978 Apr;17(2):106-12. Methods Inf Med. 1978. PMID: 661604 No abstract available.
• Active Monitoring of Adverse Drug Reactions with Neural Network Technology.

  Wu T, Gao CC, Lin JS, Zha JL. Wu T, et al. Chin Med J (Engl). 2017 Jun 20;130(12):1498-1501. doi: 10.4103/0366-6999.207468. Chin Med J (Engl). 2017. PMID: 28584215 Free PMC article. No abstract available.
• Cost-effectiveness of therapeutic drug monitoring.

  Vozeh S. Vozeh S. Clin Pharmacokinet. 1987 Sep;13(3):131-40. doi: 10.2165/00003088-198713030-00001. Clin Pharmacokinet. 1987. PMID: 3117472 Review. No abstract available.
• Commentary by a child psychiatrist in industry on the assessment of drug safety.

  Allen AJ. Allen AJ. J Child Adolesc Psychopharmacol. 2007 Jun;17(3):288-91. doi: 10.1089/cap.2007.0031. J Child Adolesc Psychopharmacol. 2007. PMID: 17630860 Review. No abstract available.